Eligibility Criteria:

Inclusion Criteria

• ME secondary to diabetes with central subfield > 280um.
• It must be safe to withhold Laser, IVS, and IV VEGF inhibitors, in the study eye for duration of the study.
• Can have received IVK, laser or IV VEGF inhibitors as long as it has been greater than 3 months from screening.

 Exclusion Criteria

OPHTHALMIC EXCLUSION- BCVA >20/320 at screening or baseline

·         Mac atrophy/scar/fibrosis/exudates in study eye that would preclude improvement in V.A.

·         Any progressive disease of retina or optic nerve other than diabetic retinopathy

·         Media opacity in study eye severe enough to interfere w/ a 3 line improvement in VA compared to baseline

·         PDR or pre proliferative that may need focal therapy w/in 16 weeks of screening.

·         IOP of >25mmHg in either eye at screening.

·         Any intra- ocular sx. in study eye except uncomplicated CE < 6months ā screening.

·         Laser in study eye w/in 3 mos ā study.

·         No IVK or anti VEGF inhibitors 3mo ā screening.

·         Use of any drug toxic to retina, lens, or optic nerve. (e.g., hyrochloroquine, ethambutaol, deferoxamine)

·         Any abnormal lab work as defined by the study.

GENERAL MEDICAL EXCLUSION-

• HBA1C > 10.  BP > 155/95.  Weigh > 110 lbs. BMI 18-40kg/m2. GFR <50ml/min. K+ >5.0
• Any Coronary history w/in 6mo ā screening.  Hx. Of heart block or pacemaker at any time.
• See coordinator for complete list of medical exclusions.
• Multiple cardiac exclusions. Have coordinator review history.
• Hx. Of angioedema from ACE inhibitors, ARBs, or aliskiren therapy.
• Use of chronic nasal/oral corticosteroids of any type, bronchodilators, MAO inhibitors, sympathomimetics, or

Ergotoids. Coordinator has more complete list.

BMI 18-40 kg/m. Must weigh at least 50kg. (110